N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Sponsor: Novo Nordisk A/S • ClinicalTrials.gov ID: NCT07770841

Registry updated: 2026-09-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

Interventions

  • Semaglutide (Drug)
    Participants will receive semaglutide orally.
  • Placebo (Drug)
    Participants will receive placebo orally.

Eligibility criteria

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) of 1. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR 2. ≥ 30.0 kg/m\^2. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records. * HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

Conditions

Overweight Obesity

Locations

  • Uni of Alabama at Birmingham — Birmingham, Alabama, United States
  • Headlands Research California, LLC — Escondido, California, United States
  • National Research Institute - Huntington Park — Huntington Park, California, United States
  • Los Angeles Institute for Metabolic Research — Los Angeles, California, United States
  • ERG Holding Company, LLC / Evolution Research Group, LLC — Delray Beach, Florida, United States
  • ERG Holding Company, LLC / Evolution Research Group, LLC — Fort Myers, Florida, United States
  • Jedidiah Clinical Research — Tampa, Florida, United States
  • East West Med Res Inst — Honolulu, Hawaii, United States
  • L-MARC Research Center — Louisville, Kentucky, United States
  • StudyMetrix Research LLC — City of Saint Peters, Missouri, United States
  • Jubilee Clinical Research, Inc. — Las Vegas, Nevada, United States
  • Corvallis Clinic PC Clinical Research Department — Corvallis, Oregon, United States
  • UPA Ctr Weight and Eating Dis — Philadelphia, Pennsylvania, United States
  • Spartanburg Medical Research — Spartanburg, South Carolina, United States
  • Cedar Health Research — Dallas, Texas, United States
  • Selma Medical Associates — Winchester, Virginia, United States
  • Anima Research Center — Alken, Belgium
  • Imelda — Bonheiden, Belgium
  • UZ Brussel - Universitair Ziekenhuis Brussel — Brussels, Belgium
  • Universitair Ziekenhuis Gent — Ghent, Belgium
  • KORMONT — Kluisbergen, Belgium
  • AIPSMC - DiMed EOOD — Haskovo, Bulgaria
  • Medical Center Zdrave Lom EOOD — Lom, Bulgaria
  • IPMC - Dr. Elizabeta Dimitrova — Petrich, Bulgaria
  • MHAT Hadzhi Dimitar OOD — Sliven, Bulgaria
  • DCC Neoklinik EAD — Sofia, Bulgaria
  • DCC 1 Velingrad EOOD — Velingrad, Bulgaria
  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus — Aarhus N, Denmark
  • Gentofte Hospital - Center for Klinisk Metabolisk Forskning — Hellerup, Denmark
  • Regionshospitalet Gødstrup, Hjertesygdomme — Herning, Denmark
  • Hôpital Privé Saint Martin_Service de chirurgie digestive — Caen, France
  • LES HOPITAUX DE CHARTRES_HOPITAL LOUIS PASTEUR_Service d'endocrinologie — Le Coudray, France
  • Hôpital Privé La Louvière_Service de chirurgie — Lille, France
  • CENTRE DE RECHERCHE CLINIQUE PORTES DU SUD_Service d'Endocrinologie-Diabétologie-Maladies Métaboliques — Vénissieux, France
  • City Hospital Kliniki Monoprosopi I.K.E. — Kalamata, Greece
  • Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit — Marousi, Greece
  • Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department — Peristeri, Greece
  • NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes — Thessaloniki, Greece
  • Thermi Clinic S.A. - Diabetes and Internal Medicine Department — Thessaloniki, Greece
  • Progress Clinical Research Amsterdam — Amsterdam, Netherlands
  • Praktijk Dokters van Nederhoven — Zwijndrecht, Netherlands
  • Progress Clinical Research Zwolle — Zwolle, Netherlands
  • Kresmed Sp. z o. o. — Bialystok, Poland
  • Athleticomed Sp. z o.o. — Bydgoszcz, Poland
  • Gierach-Med — Bygdoszcz, Poland
  • Santa Sp. z o.o. — Lodz, Poland
  • Centrum Zdrowia Metabolicznego Paweł Bogdański — Poznan, Poland
  • Velocity Nova Sp. z o.o. — Staszów, Poland
  • NBR Polska Tomasz Klodawski — Warsaw, Poland
  • Care Access Polska Sp. Z o.o. — Warsaw, Poland
  • FutureMeds Sp. z o.o. — Warsaw, Poland
  • HU de Fuenlabrada_Endocrinología — Fuenlabrada, Madrid, Spain
  • CPE Bola Azul_Endocrinología y Nutrición — Almería, Spain
  • Hosp. Vithas Sevilla_Endocrino y Nutrición — Castilleja de la Cuesta, Spain
  • Hospital Naval Ferrol — Ferrol, Spain
  • Clínica Palacios Madrid — Madrid, Spain
  • Clínica Gaias Santiago — Santiago de Compostela, Spain
  • Clínica Nuevas Tecnologías en Diabetes y Endocrinología — Seville, Spain
  • H. Infanta Luisa_Endocrino y Obesidad — Seville, Spain
  • CTC GoCo Mölndal — Mölndal, Sweden
  • Enheten för Kliniska Studier (EKS), Örebro — Örebro, Sweden
  • CTC Stockholm — Stockholm, Sweden
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record